Ultragenyx Pharmaceutical Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Cash Flow
Cash Flow by Activity
Earnings Quality (Net Income vs Operating Cash Flow)
Operating Cash Flow↑+12.7% +$24M
$-166M
Free Cash Flow↓-475.5% -$775K
$-938K
Investing Cash Flow
$117M
Financing Cash Flow↑+13285.1% +$391M
$394M
Capex↑+475.5% +$775K
$938K
Acquisitions
$0
Dividends Paid
—
Stock-Based Comp
—
D&A↓-7.9% -$751K
$9M
SBC Allocated Expense↓-6.7% -$3M
$37M